Verastem reported $87.84M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Alaunos Therapeutics USD 2.49M 108K Jun/2026
AstraZeneca USD 1.55B 28K Sep/2026
Curis USD 2M 10.93M Mar/2026
Cytokinetics USD 138.76M 14.33M Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Laboratory Of America USD 81.2M 300K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
TG Therapeutics USD 151.16M 1.92M Sep/2026
Verastem USD 87.84M 10.1M Mar/2026